Richens A, Marshall R W, Dirach J, Jansen J A, Snel S, Pedersen P C
Department of Pharmacology and Therapeutics, University of Wales College of Medicine, Heath Park, Cardiff, UK.
Drug Metabol Drug Interact. 1998;14(3):159-77. doi: 10.1515/dmdi.1998.14.3.159.
In a randomised, double blind, placebo-controlled, four-period cross-over study in 12 healthy volunteers, the potential pharmacodynamic and pharmacokinetic interactions between the new antiepileptic drug, tiagabine, and the benzodiazepine, triazolam, were investigated. A single dose of tiagabine HCl 10 mg did not enhance the sedative or cognitive effects of a single dose of the benzodiazepine triazolam 0.125 mg, although the time-course of the effects was prolonged. Furthermore, tiagabine did not produce any statistically significant effects on the pharmacokinetics of triazolam. Similarly, the pharmacokinetics of tiagabine were not modified by triazolam. Tiagabine was well tolerated when administered alone or with triazolam.
在一项针对12名健康志愿者的随机、双盲、安慰剂对照、四周期交叉研究中，对新型抗癫痫药物噻加宾与苯二氮䓬类药物三唑仑之间潜在的药效学和药代动力学相互作用进行了研究。单剂量10毫克盐酸噻加宾并未增强单剂量0.125毫克苯二氮䓬类药物三唑仑的镇静或认知作用，尽管其作用的时间过程有所延长。此外，噻加宾对三唑仑的药代动力学未产生任何具有统计学意义的影响。同样，三唑仑也未改变噻加宾的药代动力学。单独使用或与三唑仑合用时，噻加宾的耐受性良好。
